Pacylex Pharmaceuticals Inc

Pacylex Pharmaceuticals Inc. is an emerging biotech oncology company based in Edmonton, AB, dedicated to revolutionizing cancer care through innovative therapies. Specializing in developing a first-in-class, daily, oral cancer therapy, Pacylex focuses on disrupting myristoylation - a crucial process for cancer cell survival and proliferation.

With a strong emphasis on N-myristoyltransferase (NMT) inhibition therapy, Pacylex leads the way in clinical development with multiple Phase 2a programs in progress. Their flagship product, zelenirstat, an orally bioavailable myristoylation inhibitor, shows promising results in treating various solid tumor cancers and lymphomas, offering a potential alternative to traditional chemotherapies and immunotherapies.

Pacylex's cutting-edge approach targets urgent needs in cancer care, aiming to improve survival rates for patients with critical conditions such as acute myeloid leukemia and lung cancer. By eliminating tumors and inhibiting cancer growth in animal models, Pacylex Pharmaceuticals strives to bring hope to those facing daunting prognoses.

Generated from the website content